References
- Betti M, Ferranteb D, Padoanb M, et al (2011). XRCC1 and ERCC1 variants modify malignant mesothelioma risk: A case-control study. Mutat Res, 708, 11-20. https://doi.org/10.1016/j.mrfmmm.2011.01.001
- Ceppi P, Volante M, Novello S, et al (2006). ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol, 17, 1818-25. https://doi.org/10.1093/annonc/mdl300
- Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, van Meerbeeck J (2008). Advances in the sysytemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol, 5, 136-47.
- Horgan AM, Yang B, Azad AK, et al (2011). Pharmacogenetic and germline prognostic markers of lung cancer. J Thorac Oncol, 6, 296-304. https://doi.org/10.1097/JTO.0b013e3181ffe909
- Joerger M, Dejong D, Burylo A, et al (2011). Tubuline, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. Lung Cancer, 74, 31-7.
- Kapoor S (2013). ERCC1 and its role in tumor pathogenesis and progression. Urol Oncol, 31, 280-5. https://doi.org/10.1016/j.urolonc.2012.10.010
- Lee KH, Min HS, Han SW, et al (2008). ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer, 60, 401-7. https://doi.org/10.1016/j.lungcan.2007.10.014
- Li Y, Huang XE, Jin GF, et al (2011). Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751. Asian Pac J Cancer Prev, 12, 739-42.
- Li FY, Ren XB, Xie XY, Zhang J (2013a). Meta-analysis of excision repair cross-complementation group 1 (ERCC1) association with response to platinum-based chemotherapy in ovarian cancer. Asian Pac J Cancer Prev, 14, 7203-6. https://doi.org/10.7314/APJCP.2013.14.12.7203
- Li XD, Han JC, Zhang YJ, et al (2013b). Common variations of DNA repair genes are associated with response to platinumbased chemotherapy in NSCLCs. Asian Pac J Cancer Prev, 14, 145-8. https://doi.org/10.7314/APJCP.2013.14.1.145
- Martin LP, Hamilton TC, Schilder RJ (2008). Platinum resistance: the role of DNA repair pathways. Clin Cancer Res, 14, 1291-5. https://doi.org/10.1158/1078-0432.CCR-07-2238
- Metintas S, Metintas M, Ucgun I, Oner U (2002). Malignant mesothelioma due to environmental exposure to asbestos: Follow-up of a Turkish cohort living in a rural area. Chest, 122, 2224-9. https://doi.org/10.1378/chest.122.6.2224
- Olaussen KA, Dunant A, Fouret P, et al (2006). DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 355, 983-91. https://doi.org/10.1056/NEJMoa060570
- Ozkan M, Akbudak IH, Deniz K, et al (2010). Prognostic value of excision repair cross-complementing gene 1 expression for cisplatin-based chemotherapy in advanced gastric cancer. Asian Pac J Cancer Prev, 11, 181-5.
- Pagan V, Ceron L, Paccagnella A, Pizzi G (2006). 5-year prospective results of trimodality treatment for malignant pleural mesothelioma. J Cardiovasc Surg, 47, 595-601.
- Pfeifer GP, Denissenko MF, Olivier M, et al (2002). Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene, 21, 7435-51. https://doi.org/10.1038/sj.onc.1205803
- Righi L, Papotti MG, Ceppi P, et al (2010). Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexedbased chemotherapy. J Clin Oncol, 28, 1534-9. https://doi.org/10.1200/JCO.2009.25.9275
- Santoro A, O'Brien ME, Stahel RA, et al (2008). Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the international expanded access program. J Thorac Oncol, 3, 756-63. https://doi.org/10.1097/JTO.0b013e31817c73d6
- Simon GR, Sharma S, Cantor A, Smith P, Bepler G (2005). ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest, 127, 978-83. https://doi.org/10.1378/chest.127.3.978
- Zhang ZY, Tian X, Wu R, et al (2012). Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy. Asian Pac J Cancer Prev, 13, 2583-6. https://doi.org/10.7314/APJCP.2012.13.6.2583
- Zhang YY, Gu KS (2013). DNA repair capacity in peripheral blood lymphocytes predicts efficacy of platinum-based chemotherapy in patients with gastric cancer. Asian Pac J Cancer Prev, 14, 5507-12. https://doi.org/10.7314/APJCP.2013.14.9.5507
- Zimling ZG, Sorensen JB, Gerds TA, et al (2012). Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival. J Thorac Oncol, 7, 249-56. https://doi.org/10.1097/JTO.0b013e318233d6a9
Cited by
- Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis vol.18, pp.1, 2018, https://doi.org/10.1186/s12890-018-0619-3